Dangerous dynamic duo: Lactic acid and PD-1 blockade

Sheila Johnson; Marcia C Haigis; Stephanie K Dougan

doi:10.1016/j.ccell.2022.01.008

Dangerous dynamic duo: Lactic acid and PD-1 blockade

Cancer Cell. 2022 Feb 14;40(2):127-130. doi: 10.1016/j.ccell.2022.01.008. Epub 2022 Jan 28.

Authors

Sheila Johnson¹, Marcia C Haigis¹, Stephanie K Dougan²

Affiliations

¹ Department of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
² Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Immunology, Blavatnik Institute, Harvard Medical School, Harvard Medical School, Boston, MA, USA. Electronic address: stephanie_dougan@dfci.harvard.edu.

PMID: 35093211
DOI: 10.1016/j.ccell.2022.01.008

Abstract

In this issue of Cancer Cell, Kumagai et al. reveal lactic acid as a mediator of checkpoint blockade resistance. Tumor-derived lactic acid promotes T regulatory cell (Treg) activity and impairs CD8⁺ T cell function. PD-1 blockade synergizes with lactic acid to enhance Treg suppression and impede antitumor immunity.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

CD8-Positive T-Lymphocytes / immunology
Lactic Acid*
Programmed Cell Death 1 Receptor* / immunology
T-Lymphocytes, Regulatory / immunology

Substances

Programmed Cell Death 1 Receptor
Lactic Acid

Grants and funding

R01 AI158488/AI/NIAID NIH HHS/United States